Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Allergan PLC, consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Accrued third-party rebates	2,001,800)	1,832,100)	1,713,700)	1,595,500)	1,281,600)
Litigation-related reserves and legal fees	1,250,700)	92,000)	78,300)	101,100)	213,500)
Accrued payroll and related benefits	830,300)	694,300)	635,600)	543,500)	409,700)
Accrued returns and other allowances	596,700)	527,800)	466,200)	295,900)	288,400)
Accrued R&D expenditures	184,800)	215,500)	165,900)	154,000)	384,100)
Interest payable	189,500)	191,400)	245,900)	294,200)	312,000)
Royalties payable	216,900)	155,100)	189,200)	146,600)	126,900)
Accrued pharmaceutical fees	125,900)	145,300)	186,400)	221,300)	162,200)
Accrued severance, retention and other shutdown costs	12,700)	71,600)	132,800)	86,200)	110,400)
Accrued non-provision taxes	64,600)	68,500)	76,500)	55,000)	100,300)
Accrued selling and marketing expenditures	61,300)	61,100)	53,000)	95,900)	127,200)
Current portion of contingent consideration obligations	12,100)	8,300)	56,200)	511,000)	79,900)
Dividends payable	1,100)	1,400)	24,600)	23,200)	23,900)
Other accrued expenses	409,900)	373,000)	1,192,600)	670,700)	360,000)
Accrued expenses	5,958,300)	4,437,400)	5,216,900)	4,794,100)	3,980,100)
Accounts payable	390,400)	349,800)	324,500)	224,900)	369,400)
Accounts payable and accrued expenses	6,348,700)	4,787,200)	5,541,400)	5,019,000)	4,349,500)
Income taxes payable	65,100)	72,400)	74,900)	57,800)	54,200)
Current portion of long-term debt and capital leases	4,532,500)	868,300)	4,231,800)	2,797,900)	2,432,800)
Current portion of lease liability, operating	124,400)	—)	—)	—)	—)
Current liabilities held for sale	—)	—)	—)	—)	1,491,800)
Current liabilities	11,070,700)	5,727,900)	9,848,100)	7,874,700)	8,328,300)
Long-term debt and capital leases, excluding current portion	18,116,500)	22,929,400)	25,843,500)	29,970,800)	40,293,400)
Lease liability, operating, excluding current portion	446,100)	—)	—)	—)	—)
Acquisition related contingent consideration liabilities	377,300)	336,300)	420,700)	661,100)	788,100)
Long-term pension and post retirement liability	144,100)	166,500)	162,700)	201,600)	222,100)
Legacy Allergan deferred executive compensation	89,200)	90,800)	113,800)	111,700)	117,900)
Accrued R&D milestone	75,000)	75,000)	—)	—)	—)
Long-term contractual obligations	—)	43,200)	45,200)	25,300)	26,400)
Deferred revenue	26,600)	36,100)	37,900)	15,700)	18,200)
Product warranties	29,200)	27,900)	28,700)	28,100)	28,400)
Long-term severance and restructuring liabilities	10,800)	14,200)	53,100)	22,000)	34,900)
Other long-term liabilities	48,700)	92,000)	24,800)	19,500)	26,000)
Other long-term liabilities	800,900)	882,000)	886,900)	1,085,000)	1,262,000)
Long-term liabilities held for sale	—)	—)	—)	—)	580,100)
Other taxes payable	1,704,800)	1,615,500)	1,573,900)	886,200)	801,900)
Deferred tax liabilities	4,363,700)	5,501,800)	6,352,400)	12,969,100)	7,985,700)
Long-term liabilities	25,432,000)	30,928,700)	34,656,700)	44,911,100)	50,923,100)
Total liabilities	36,502,700)	36,656,600)	44,504,800)	52,785,800)	59,251,400)
Preferred shares, $0.0001 par value per share	—)	—)	4,929,700)	4,929,700)	4,929,700)
Ordinary shares; $0.0001 par value per share	—)	—)	—)	—)	—)
Additional paid-in capital	55,974,900)	56,510,000)	54,013,500)	53,958,900)	68,508,300)
Retained earnings	991,500)	7,258,900)	12,957,200)	18,342,500)	3,647,500)
Accumulated other comprehensive income (loss)	1,207,200)	1,345,200)	1,920,700)	(1,038,400)	(494,100)
Shareholders’ equity	58,173,600)	65,114,100)	73,821,100)	76,192,700)	76,591,400)
Noncontrolling interest	22,800)	16,900)	16,000)	7,800)	(2,100)
Total equity	58,196,400)	65,131,000)	73,837,100)	76,200,500)	76,589,300)
Total liabilities and equity	94,699,100)	101,787,600)	118,341,900)	128,986,300)	135,840,700)

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Allergan PLC current liabilities decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Allergan PLC long-term liabilities decreased from 2017 to 2018 and from 2018 to 2019.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Allergan PLC total liabilities decreased from 2017 to 2018 and from 2018 to 2019.
Shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Allergan PLC shareholders’ equity decreased from 2017 to 2018 and from 2018 to 2019.

Allergan PLC (NYSE:AGN)

Balance Sheet: Liabilities and Stockholders’ Equity